Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial
- 29 January 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 397 (10275), 682-694
- https://doi.org/10.1016/s0140-6736(21)00241-5
Abstract
No abstract availableKeywords
Funding Information
- Coalition for Epidemic Preparedness Innovations
This publication has 25 references indexed in Scilit:
- Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticityVaccine, 2019
- Safety of AS03-adjuvanted influenza vaccines: A review of the evidenceVaccine, 2019
- Pituitary macroadenoma presenting as severe hyponatremia: a case reportJournal of Medical Case Reports, 2019
- Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsyProceedings of the National Academy of Sciences of the United States of America, 2018
- Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivoScientific Reports, 2017
- Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike ProteinViruses, 2012
- Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of ageVaccine, 2012
- Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized StudyThe Journal of Infectious Diseases, 2011
- Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacyExpert Opinion on Biological Therapy, 2007
- Hyponatremia and pituitary adenoma: Think twice about the etiopathogenesisJournal of Endocrinological Investigation, 2006